-
Product Insights
NewUrinary Tract Infections – Drugs In Development, 2024
Empower your strategies with our Urinary Tract Infections – Drugs In Development, 2024 report and make more profitable business decisions. A urinary tract infection (UTI) is a bacterial infection that can occur in any part of the urinary system, including the kidneys, bladder, ureters, and urethra. Common symptoms include pain or burning during urination, frequent urination, urgency, lower abdominal discomfort, and cloudy or foul-smelling urine. UTIs are more common in women, and risk factors include factors such as sexual activity, urinary...
-
Product Insights
NewAcute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2024
Empower your strategies with our Acute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2024 report and make more profitable business decisions. Acute renal failure occurs when the kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases, and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure, and kidney diseases. Treatment includes antibiotics and diuretics. The Acute Renal Failure (ARF) (Acute...
-
Product Insights
NewRetinal Degeneration – Drugs In Development, 2024
Empower your strategies with our Retinal Degeneration – Drugs In Development, 2024 report and make more profitable business decisions. Retinal degeneration refers to a group of diseases that cause progressive damage to the cells of the retina, the light-sensitive tissue at the back of the eye crucial for vision. These conditions lead to a gradual loss of vision, which can range from mild to severe and can eventually result in blindness. There are several types of retinal degenerative diseases, including: Retinitis...
-
Product Insights
NewChemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2024
Empower your strategies with our Chemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes, and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy, and type of chemotherapeutic agent. The Chemotherapy Induced Peripheral Neuropathy drugs in development market research report provide comprehensive information on the therapeutics under development for Chemotherapy...
-
Product Insights
NewAutism Spectrum Disorder (ASD) – Drugs In Development, 2024
Empower your strategies with our Autism Spectrum Disorder (ASD) – Drugs In Development, 2024 report and make more profitable business decisions. Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. Symptoms range from mild to severe, forming a spectrum. Individuals with ASD may have difficulties in understanding social cues, expressing emotions, and engaging in reciprocal conversations. Sensory sensitivities are common, affecting responses to stimuli. Early intervention and tailored support can enhance communication...
-
Product Insights
NewMELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) – Drugs In Development, 2024
Empower your strategies with our MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) – Drugs In Development, 2024 report and make more profitable business decisions. Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is one of the family of mitochondrial diseases. A feature of this diseases is that it is caused by defects in the mitochondrial genome which is inherited purely from the female parent. The most common MELAS mutation is mitochondrial mutation, mtDNA, referred to as m.3243A>G. Symptoms typically...
-
Product Insights
NewKeratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes...
-
Product Insights
NewChronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024
Empower your strategies with our Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease (Chronic Renal...
-
Product Insights
NewKeratoconjunctivitis – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities. The Keratoconjunctivitis drugs in development market...